Cajsa Aranäs – Gut-brain peptides and drugs of abuse
Dissertation for Medicine Doctoral degree at Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Pharmacology
Full thesis title
Gut-brain peptides and drugs of abuse: highlighting the role of GLP-1 and amylin
Opponent and examining committee
Opponent: Professor Stefan Trapp, Department of Neuroscience, Physiology & Pharmacology, University College London, London, UK
Examining committee: Professor Ville Wallenius (ordf.),, Associate Professor Anders Hammarberg (KI) and Associate Professor Magdalena Taube
Good to know
The disputation is held in English
Welcome to attend online via streaming, via Zoom Webinar: press pink button above to join the webinar.
Chairperson of the defence: Angela Äbelö
Therapeutic targets for substance use disorders
Substance use disorders (SUD), such as alcohol use disorder and cocaine use disorder, are complex and multifaceted conditions influenced by various biological, psychological, and environmental factors. Central to the development and maintenance of SUD are the rewarding effects of the drug of interest.
Gut-brain peptides, such as glucagon-like peptide 1 (GLP-1) and amylin, have been shown to reduce alcohol and cocaine consumption in rodent models, tentatively by attenuating drug-in-duced reward.
The overall aim of this thesis was to explore the role of GLP-1 and amylin as therapeutic targets for alcohol use disorder and cocaine use disorder.
